Cristina Arce1,2, Diana Vicente1, Vanessa Segura1, Nicla Flacco1, Fermi Montó1,2, Luis Almenar3, Jaime Agüero3, Joaquín Rueda3, Francesc Jiménez-Altayó4, Elisabet Vila4, Maria Antonia Noguera1,2, Pilar D'Ocon1,2, Maria Dolores Ivorra1,2. 1. Departamento de Farmacología, Facultad de Farmacia, Universitat de València, Burjassot, Spain. 2. Estructura de Recerca Interdisciplinar en Biotecnologia i Biomedicina (ERI BIOTECMED), Universitat de València, Burjassot, Spain. 3. Unidad de Insuficiencia Cardiaca y Trasplantes, Servicio de Cardiología, Hospital Universitario La Fe, Valencia, Spain. 4. Facultat de Medicina, Departament de Farmacologia, Terapèutica i Toxicologia, Institut de Neurociències, Universitat Autònoma de Barcelona, Bellaterra (Cerdanyola del Vallès), Spain.
Abstract
BACKGROUND AND PURPOSE: A NO-mediated desensitization of vasoconstrictor responses evoked by stimulation of α1 -adrenoceptors has been reported in different vessels. We investigated the involvement of each α1 -adrenoceptor subtype and constitutive NOS isoforms and the influence of ageing and hypertension on this process. EXPERIMENTAL APPROACH: Wistar and spontaneously hypertensive rats (SHR), 16, 32, 52 and 72 weeks-old, were used to evaluate the desensitization process. Expression of α1 -adrenoceptor subtypes, endothelial NOS (eNOS) and neuronal NOS (nNOS) were determined in rat aorta and left ventricle (LV). Expression levels were also evaluated in LV of a group of heart failure patients with a wide age range. KEY RESULTS: Repeated application of phenylephrine decreased subsequent α1 -adrenoceptor-mediated vasoconstriction by increasing nNOS protein expression in aorta, but not in tail or mesenteric resistance arteries, where mRNA levels of nNOS were undetectable. This desensitization process disappeared in the absence of endothelium or in the presence of L-NAME (100 μM), nNOS inhibitors, SMTC (1 μM) and TRIM (100 μM), and 5-methylurapidil (100 nM, α1A -antagonist), but not BMY7378 (10 nM, α1D -antagonist). The α1A /nNOS-mediated desensitization was absent in aged SHR and Wistar animals, where the expression of α1A -adrenoceptors was reduced in aorta and LV. In human LV, a negative correlation was found between age and α1A -adrenoceptor expression. CONCLUSIONS AND IMPLICATIONS: The α1A -adrenoceptor subtype, through endothelial nNOS-derived NO, may act as a physiological 'brake' against the detrimental effects of excessive α1 -adrenoceptor-mediated vasoconstriction. Reduced α1A -adrenoceptor- and nNOS-mediated desensitization in aged patients could be involved in the age-dependent elevation of adrenergic activity.
BACKGROUND AND PURPOSE: A NO-mediated desensitization of vasoconstrictor responses evoked by stimulation of α1 -adrenoceptors has been reported in different vessels. We investigated the involvement of each α1 -adrenoceptor subtype and constitutive NOS isoforms and the influence of ageing and hypertension on this process. EXPERIMENTAL APPROACH: Wistar and spontaneously hypertensiverats (SHR), 16, 32, 52 and 72 weeks-old, were used to evaluate the desensitization process. Expression of α1 -adrenoceptor subtypes, endothelial NOS (eNOS) and neuronal NOS (nNOS) were determined in rat aorta and left ventricle (LV). Expression levels were also evaluated in LV of a group of heart failurepatients with a wide age range. KEY RESULTS: Repeated application of phenylephrine decreased subsequent α1 -adrenoceptor-mediated vasoconstriction by increasing nNOS protein expression in aorta, but not in tail or mesenteric resistance arteries, where mRNA levels of nNOS were undetectable. This desensitization process disappeared in the absence of endothelium or in the presence of L-NAME (100 μM), nNOS inhibitors, SMTC (1 μM) and TRIM (100 μM), and 5-methylurapidil (100 nM, α1A -antagonist), but not BMY7378 (10 nM, α1D -antagonist). The α1A /nNOS-mediated desensitization was absent in aged SHR and Wistar animals, where the expression of α1A -adrenoceptors was reduced in aorta and LV. In human LV, a negative correlation was found between age and α1A -adrenoceptor expression. CONCLUSIONS AND IMPLICATIONS: The α1A -adrenoceptor subtype, through endothelial nNOS-derived NO, may act as a physiological 'brake' against the detrimental effects of excessive α1 -adrenoceptor-mediated vasoconstriction. Reduced α1A -adrenoceptor- and nNOS-mediated desensitization in aged patients could be involved in the age-dependent elevation of adrenergic activity.
Authors: T Tanabe; S Maeda; T Miyauchi; M Iemitsu; M Takanashi; Y Irukayama-Tomobe; T Yokota; H Ohmori; M Matsuda Journal: Acta Physiol Scand Date: 2003-05
Authors: Anna Csiszar; Zoltan Ungvari; John G Edwards; Pawel Kaminski; Michael S Wolin; Akos Koller; Gabor Kaley Journal: Circ Res Date: 2002-06-14 Impact factor: 17.367
Authors: N Flacco; V Segura; M Perez-Aso; S Estrada; J F Seller; F Jiménez-Altayó; M A Noguera; P D'Ocon; E Vila; M D Ivorra Journal: Br J Pharmacol Date: 2013-05 Impact factor: 8.739
Authors: Nicla Flacco; Jaime Parés; Eva Serna; Vanessa Segura; Diana Vicente; Miguel Pérez-Aso; María Antonia Noguera; María Dolores Ivorra; John C McGrath; Pilar D'Ocon Journal: Pharmacol Res Perspect Date: 2013-08-28
Authors: Emanuella Feitosa de Carvalho; Kalinne Kelly Lima Gadelha; Daniel Maia Nogueira de Oliveira; Karine Lima-Silva; Francisco José Batista-Lima; Teresinha Silva de Brito; Suliana Mesquita Paula; Moisés Tolentino Bento da Silva; Armênio Aguiar Dos Santos; Pedro Jorge Caldas Magalhães Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2019-08-16 Impact factor: 3.000
Authors: María Bové; Fermi Monto; Paloma Guillem-Llobat; M Dolores Ivorra; M Antonia Noguera; Andrea Zambrano; M Salome Sirerol-Piquer; Ana Cristina Requena; Mauricio García-Alonso; Teresa Tejerina; José T Real; Isabel Fariñas; Pilar D'Ocon Journal: Front Endocrinol (Lausanne) Date: 2021-03-18 Impact factor: 5.555
Authors: Samuel J Bose; Matthew J Read; Emily Akerman; Rebecca A Capel; Thamali Ayagama; Angela Russell; Derek A Terrar; Manuela Zaccolo; Rebecca A B Burton Journal: Front Pharmacol Date: 2022-08-29 Impact factor: 5.988